Literature DB >> 21613930

Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction.

Donald F Zoz1, William E Lawson, Timothy S Blackwell.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive dyspnea, interstitial infiltrates in lung parenchyma and restriction on pulmonary function testing. IPF is the most common and severe of the idiopathic interstitial pneumonias, with most individuals progressing to respiratory failure. Multiple lines of evidence reveal prominent roles for alveolar epithelial cells (AECs) in disease. The current disease paradigm is that ongoing or repetitive injurious stimuli in the presence of a genetic or acquired dysfunctional type II AEC phenotype results in increased AEC injury/apoptosis, deficiencies in regeneration of normal alveolar structure and aberrant lung repair and fibroblast activation, leading to progressive fibrosis. Although the nature of injurious events and processes involved in aberrant repair of the alveolar epithelium are not well understood, ongoing investigations provide hope to better understand mechanisms by which AECs maintain homeostasis or contribute to fibrosis. These strategies may hold promise for developing novel treatment approaches for IPF.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613930      PMCID: PMC3103044          DOI: 10.1097/MAJ.0b013e31821a9d8e

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  38 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  A mutation in the surfactant protein C gene associated with familial interstitial lung disease.

Authors:  L M Nogee; A E Dunbar; S E Wert; F Askin; A Hamvas; J A Whitsett
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

Review 3.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

4.  Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor.

Authors:  K Kuwano; R Kunitake; T Maeyama; N Hagimoto; M Kawasaki; T Matsuba; M Yoshimi; I Inoshima; K Yoshida; N Hara
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-02       Impact factor: 5.464

5.  Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.

Authors:  Alan Q Thomas; Kirk Lane; John Phillips; Melissa Prince; Cheryl Markin; Marcy Speer; David A Schwartz; Radhika Gaddipati; Annis Marney; Joyce Johnson; Richard Roberts; Jonathan Haines; Mildred Stahlman; James E Loyd
Journal:  Am J Respir Crit Care Med       Date:  2002-05-01       Impact factor: 21.405

6.  Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis.

Authors:  Amber L Degryse; Harikrishna Tanjore; Xiaochuan C Xu; Vasiliy V Polosukhin; Brittany R Jones; Frank B McMahon; Linda A Gleaves; Timothy S Blackwell; William E Lawson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-06-18       Impact factor: 5.464

7.  Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF.

Authors:  L H Pan; K Yamauchi; M Uzuki; T Nakanishi; M Takigawa; H Inoue; T Sawai
Journal:  Eur Respir J       Date:  2001-06       Impact factor: 16.671

8.  Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor.

Authors:  R Wang; O Ibarra-Sunga; L Verlinski; R Pick; B D Uhal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-07       Impact factor: 5.464

Review 9.  Idiopathic pulmonary fibrosis.

Authors:  T J Gross; G W Hunninghake
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

Review 10.  Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy.

Authors:  M Selman; T E King; A Pardo
Journal:  Ann Intern Med       Date:  2001-01-16       Impact factor: 25.391

View more
  48 in total

1.  Right place, right time: the evolving role of herpesvirus infection as a "second hit" in idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; William E Lawson; Timothy S Blackwell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-16       Impact factor: 5.464

Review 2.  Lung regeneration: a tale of mice and men.

Authors:  Maria C Basil; Edward E Morrisey
Journal:  Semin Cell Dev Biol       Date:  2019-11-21       Impact factor: 7.727

3.  Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis.

Authors:  Christina Morse; Tracy Tabib; John Sembrat; Kristina L Buschur; Humberto Trejo Bittar; Eleanor Valenzi; Yale Jiang; Daniel J Kass; Kevin Gibson; Wei Chen; Ana Mora; Panayiotis V Benos; Mauricio Rojas; Robert Lafyatis
Journal:  Eur Respir J       Date:  2019-08-22       Impact factor: 16.671

4.  Telomere dysfunction causes alveolar stem cell failure.

Authors:  Jonathan K Alder; Christina E Barkauskas; Nathachit Limjunyawong; Susan E Stanley; Frant Kembou; Rubin M Tuder; Brigid L M Hogan; Wayne Mitzner; Mary Armanios
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-03       Impact factor: 11.205

5.  Hsp90 regulation of fibroblast activation in pulmonary fibrosis.

Authors:  Vishwaraj Sontake; Yunguan Wang; Rajesh K Kasam; Debora Sinner; Geereddy B Reddy; Anjaparavanda P Naren; Francis X McCormack; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2017-02-23

6.  Angiotensin II: tapping the cell cycle machinery to kill endothelial cells.

Authors:  Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-08-10       Impact factor: 5.464

Review 7.  The UPR and lung disease.

Authors:  Fabiola Osorio; Bart Lambrecht; Sophie Janssens
Journal:  Semin Immunopathol       Date:  2013-03-28       Impact factor: 9.623

8.  Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes.

Authors:  Rongrong Wei; Chong Li; Min Zhang; Yava L Jones-Hall; Jamie L Myers; Imre Noth; Wanqing Liu
Journal:  Transl Res       Date:  2013-12-17       Impact factor: 7.012

9.  Neonatal hyperoxia increases sensitivity of adult mice to bleomycin-induced lung fibrosis.

Authors:  Min Yee; Bradley W Buczynski; B Paige Lawrence; Michael A O'Reilly
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-20       Impact factor: 6.914

Review 10.  Nonmicrobial-mediated inflammatory airway diseases--an update.

Authors:  Polani B Ramesh Babu; P Krishnamoorthy
Journal:  J Physiol Biochem       Date:  2013-11-29       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.